Adagio knows its COVID-19 antibody works against old variants. Can it win EUA in the era of omicron?

Adagio knows its COVID-19 antibody works against old variants. Can it win EUA in the era of omicron?

Source: 
Fierce Biotech
snippet: 

Adagio Therapeutics has spied a path to FDA authorization for its tarnished COVID-19 antibody. Having been brought low in an omicron farrago, Adagio is now looking to positive phase 2/3 data against earlier variants to help secure ADG20 a spot among the arsenal of preventive and therapeutic antibodies.